A recently-approved treatment could take a BiTE out of small cell lung cancer by using a person's own body to fight back.

There are two main types of lung cancer. Small-cell lung cancer (SCLC), sometimes called small-cell carcinoma, causes about 10%-15% of all lung cancer. Non-small-cell lung cancer (NSCLC ...

Amidst the continued struggle to treat non-small-cell lung cancer, a new study led by Stanford University scientists suggests that a patient's response to immunotherapy may hinge on how immune cells ...

Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was ...

Merck (MRK) stock falls as the company withdraws U.S. marketing application for lung cancer therapy HER3-DXd developed with ...

Patients with extensive-stage SCLC often respond to induction therapy, but the disease tends to progress rapidly after cytotoxic therapy ends, said Jared Weiss, MD, of the University of North Carolina ...

Imdelltra (tarlatamab-dlle) has shown statistically significant and clinically meaningful improvement in overall survival compared to local standard-of-care chemotherapy among patients with small cell ...

Roche’s plan to bolster Tecentriq’s position in small cell lung cancer with Jazz Pharmaceuticals’ Zepzelca has paid off. | ...

There are two main types of lung cancer: non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). Several subtypes exist within these categories, and there are a few other ...

OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced that three of its research abstracts have been accepted for poster ...

Health Canada has granted a Notice of Compliance with conditions (NOC/c) for Tagrisso® (osimertinib) for the treatment of patients with locally advanced, unresectable (stage III) non-small cell lung ...